"Bile Duct Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the BILE DUCTS.
Descriptor ID |
D001650
|
MeSH Number(s) |
C04.588.274.120.250 C06.130.120.120 C06.130.320.120 C06.301.120.250
|
Concept/Terms |
Bile Duct Neoplasms- Bile Duct Neoplasms
- Bile Duct Neoplasm
- Neoplasm, Bile Duct
- Neoplasms, Bile Duct
Bile Duct Cancer- Bile Duct Cancer
- Bile Duct Cancers
- Cancer, Bile Duct
- Cancers, Bile Duct
- Cancer of the Bile Duct
- Cancer of Bile Duct
|
Below are MeSH descriptors whose meaning is more general than "Bile Duct Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Bile Duct Neoplasms".
This graph shows the total number of publications written about "Bile Duct Neoplasms" by people in this website by year, and whether "Bile Duct Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 2 | 0 | 2 |
1995 | 3 | 1 | 4 |
1996 | 2 | 1 | 3 |
1997 | 1 | 0 | 1 |
1998 | 0 | 1 | 1 |
1999 | 2 | 0 | 2 |
2000 | 3 | 1 | 4 |
2001 | 1 | 0 | 1 |
2002 | 4 | 2 | 6 |
2003 | 4 | 0 | 4 |
2004 | 7 | 0 | 7 |
2005 | 3 | 1 | 4 |
2006 | 6 | 3 | 9 |
2007 | 12 | 1 | 13 |
2008 | 9 | 3 | 12 |
2009 | 8 | 1 | 9 |
2010 | 8 | 1 | 9 |
2011 | 12 | 0 | 12 |
2012 | 6 | 2 | 8 |
2013 | 1 | 2 | 3 |
2014 | 5 | 0 | 5 |
2015 | 9 | 1 | 10 |
2016 | 8 | 2 | 10 |
2017 | 11 | 2 | 13 |
2018 | 6 | 2 | 8 |
2019 | 5 | 1 | 6 |
2020 | 12 | 2 | 14 |
2021 | 18 | 0 | 18 |
2022 | 21 | 0 | 21 |
2023 | 25 | 0 | 25 |
2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bile Duct Neoplasms" by people in Profiles.
-
Comprehensive Immunogenomic Profiling of IDH1-/2-Altered Cholangiocarcinoma. JCO Precis Oncol. 2024 Mar; 8:e2300544.
-
Revisiting the Malignant Masquerade at the Liver Hilum: Have We Made Progress? Ann Surg Oncol. 2024 May; 31(5):3062-3068.
-
Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers. Clin Cancer Res. 2023 12 01; 29(23):4853-4862.
-
Convergent MAPK pathway alterations mediate acquired?resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma. J Hepatol. 2024 Feb; 80(2):322-334.
-
Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors. Oncologist. 2023 Nov 02; 28(11):928-943.
-
Independent of Primary Sclerosing Cholangitis and Cirrhosis, Early Adulthood Obesity Is Associated with Cholangiocarcinoma. Cancer Epidemiol Biomarkers Prev. 2023 10 02; 32(10):1338-1347.
-
Great Debates: Neoadjuvant Therapy Should be Routinely Given for High-Risk Cholangiocarcinoma. Ann Surg Oncol. 2023 12; 30(13):7960-7965.
-
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations. Cancer Discov. 2023 09 06; 13(9):2012-2031.
-
What Role Does Radiotherapy Play in the Molecular Era for Intrahepatic Cholangiocarcinoma? Cancer J. 2023 Sep-Oct 01; 29(5):272-278.
-
Imaging Findings in Cirrhotic Liver: Pearls and Pitfalls for Diagnosis of Focal Benign and Malignant Lesions. Radiographics. 2023 09; 43(9):e230043.